Literature DB >> 29431623

Prevalence and risk factors for venous thromboembolism in children with sickle cell disease: an administrative database study.

Riten Kumar1, Joseph Stanek2, Susan Creary1, Amy Dunn1, Sarah H O'Brien1.   

Abstract

A hypercoagulable state resulting in increased venous thromboembolism (VTE) has been described in adults with sickle cell disease (SCD), but similar data for children are lacking. The objective of this retrospective cohort study was to describe the rate of VTE and risk factors associated with VTE in children with SCD across tertiary-care children's hospitals in the United States between the years 2009 and 2015. We used the Pediatric Health Information System database to investigate all pediatric patients with SCD admitted to 1 of 48 participating institutions between 1 January 2009 and 30 September 2015. International Classification of Disease, Ninth Edition, Clinical Modification codes were used to identify index thromboembolic events and chronic medical conditions known to be associated with VTE. Billing codes were used to identify central venous line (CVL) placement and pharmaceutical billing codes to identify estrogen containing oral-contraceptive use. Logistic regression analysis was used to study the association among unique patient characteristics, VTE, and death. 10 454 eligible subjects with SCD were identified. Median age (±interquartile range) of study cohort was 10 (±11) years. 181 subjects (1.7%) developed an index venous thromboembolic event during the study period. Median age at VTE diagnosis was 15.9 (±7.4) years. On multivariable logistic regression analysis, CVL placement, chronic renal disease, history of stroke, female sex, length of hospitalization, intensive care unit utilization, and older age were associated with VTE. After adjusting for other variables, VTE was independently associated with death. In summary, VTE can occur in pediatric patients with SCD. CVL placement is a modifiable risk factor for VTE development.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2018        PMID: 29431623      PMCID: PMC5812330          DOI: 10.1182/bloodadvances.2017012336

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  43 in total

1.  Protein C and protein S in homozygous sickle cell disease: does hepatic dysfunction contribute to low levels?

Authors:  J G Wright; R Malia; P Cooper; P Thomas; F E Preston; G R Serjeant
Journal:  Br J Haematol       Date:  1997-09       Impact factor: 6.998

2.  Increasing rates of thrombosis in children with congenital heart disease undergoing cardiac surgery.

Authors:  Michael Silvey; Matt Hall; Eryn Bilynsky; Shannon L Carpenter
Journal:  Thromb Res       Date:  2017-12-13       Impact factor: 3.944

3.  Significant increase in clopidogrel use across U.S. children's hospitals.

Authors:  Chiara Gentilomo; Yuan-Shung Huang; Leslie Raffini
Journal:  Pediatr Cardiol       Date:  2010-12-07       Impact factor: 1.655

Review 4.  Cathlink 20: a subcutaneous implanted central venous access device used in children with sickle cell disease on long-term erythrocytapheresis--a report of low complication rates.

Authors:  Ashok Raj; Salvatore Bertolone; Sheldon Bond; Diane Burnett; Audria Denker
Journal:  Pediatr Blood Cancer       Date:  2005-06-15       Impact factor: 3.167

5.  Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients.

Authors:  L M Hilliard; B F Williams; A E Lounsbury; T H Howard
Journal:  Am J Hematol       Date:  1998-09       Impact factor: 10.047

Review 6.  Skull bone infarctive crisis and deep vein thrombosis in homozygous sickle cell disease- case report and review of the literature.

Authors:  N A Alli; R D Wainwright; D Mackinnon; S Poyiadjis; G Naidu
Journal:  Hematology       Date:  2007-04       Impact factor: 2.269

Review 7.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

8.  Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007.

Authors:  Leslie Raffini; Yuan-Shung Huang; Char Witmer; Chris Feudtner
Journal:  Pediatrics       Date:  2009-09-07       Impact factor: 7.124

9.  Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications.

Authors:  A Abdul-Rauf; M Gauderer; K Chiarucci; B Berman
Journal:  J Pediatr Hematol Oncol       Date:  1995-11       Impact factor: 1.289

Review 10.  Hypercoagulability in sickle cell disease: a curious paradox.

Authors:  Kenneth I Ataga; Eugene P Orringer
Journal:  Am J Med       Date:  2003-12-15       Impact factor: 4.965

View more
  9 in total

1.  Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease.

Authors:  Andrew Srisuwananukorn; Rasha Raslan; Xu Zhang; Binal N Shah; Jin Han; Michel Gowhari; Robert E Molokie; Victor R Gordeuk; Santosh L Saraf
Journal:  Blood Adv       Date:  2020-05-12

2.  High incidence of venous thromboembolism recurrence in patients with sickle cell disease.

Authors:  Ann Brunson; Theresa Keegan; Anjlee Mahajan; Richard White; Ted Wun
Journal:  Am J Hematol       Date:  2019-06-12       Impact factor: 10.047

Review 3.  How I diagnose and treat venous thromboembolism in sickle cell disease.

Authors:  Arun S Shet; Ted Wun
Journal:  Blood       Date:  2018-05-15       Impact factor: 22.113

4.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Authors:  Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

5.  Vascular Instability and Neurological Morbidity in Sickle Cell Disease: An Integrative Framework.

Authors:  Hanne Stotesbury; Jamie M Kawadler; Patrick W Hales; Dawn E Saunders; Christopher A Clark; Fenella J Kirkham
Journal:  Front Neurol       Date:  2019-08-13       Impact factor: 4.003

6.  Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia - lessons learned for prophylaxis.

Authors:  Salam Alkindi; Anwaar R Al-Ghadani; Samah R Al-Zeheimi; Said Y Alkindi; Naglaa Fawaz; Samir K Ballas; Anil V Pathare
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

7.  How we approach thrombosis risk in children with COVID-19 infection and MIS-C.

Authors:  Anjali A Sharathkumar; E Vincent S Faustino; Clifford M Takemoto
Journal:  Pediatr Blood Cancer       Date:  2021-05-06       Impact factor: 3.167

8.  Gender-Related Differences in Sickle Cell Disease in a Pediatric Cohort: A Single-Center Retrospective Study.

Authors:  Giulia Ceglie; Margherita Di Mauro; Isabella Tarissi De Jacobis; Francesca de Gennaro; Martina Quaranta; Carlo Baronci; Alberto Villani; Giuseppe Palumbo
Journal:  Front Mol Biosci       Date:  2019-12-05

9.  The molecular basis for the prothrombotic state in sickle cell disease.

Authors:  Arun S Shet; Maria A Lizarralde-Iragorri; Rakhi P Naik
Journal:  Haematologica       Date:  2020-10-01       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.